Experimental Psychologist & Research Assistant Professor @UMich | Michigan Psychedelic Center (M-PsyC) | Chronic Pain and Fatigue Research Center (CPFRC)
Ann Arbor, MI
- Tweets 937
- Following 981
- Followers 3,021
- Likes 5,220
Jacob S. Aday, Ph.D. retweeted
1/ Happy to share our new study, published today, looking to better understand an intriguing feature of the psychedelic experience: Why can psychedelic experiences feel profoundly familiar, even when what is being experienced is novel?
@ManojDoss
& Akira O'Connor
3
1
9
1,986
Jacob S. Aday, Ph.D. retweeted
A new study suggests that consuming psilocin directly—rather than its precursor, psilocybin—provides a similar psychedelic experience with fewer side effects. Researchers also found that taking the drug under the tongue produced emotional breakthroughs… dlvr.it/TVLJGq
10
55
389
12,917
Jacob S. Aday, Ph.D. retweeted
New paper from our @TrPR_Program at @UCSF_BCHSI
We compared the effects of psilocin vs. psilocybin. People often don't know, but psilocybin is actually not what makes you trip, it is psilocin, psilocybin's metabolite! Here we found that ... well, they are pretty much the same as one would expect :)
Great breakdown below by co-author👇
“A randomized crossover trial comparing the acute physiological and psychological effects of botanical formulations of oral psilocybin, oral psilocin, and sublingual psilocin“ is now published in Journal of Psychopharmacology.
journals.sagepub.com/doi/ful…
4
5
16
1,964
“A randomized crossover trial comparing the acute physiological and psychological effects of botanical formulations of oral psilocybin, oral psilocin, and sublingual psilocin“ is now published in Journal of Psychopharmacology.
journals.sagepub.com/doi/ful…
1
7
20
3,261
Sublingual psilocin was well tolerated, but higher dosages than those tested (e.g., 2.18, 4.36, or 8 mg) are likely needed to achieve similar psychoactive effects as the “standard” 25mg of oral psilocybin.
4
2
133
Coauthored with Marlene L. Tai, @psybalazs, Amanda E. Downey, Lisa Fredenburg, Kimberly Sakai, Cesar Molina, Gisele Fernandes-Osterhold, Ellen R. Bradley, Maddie Pantoni, Ryan Moss, Benjamin Lightburn, Franziska Plessow, Aoife O’Donovan, & Josh D. Woolley
1
2
254
“Microdosing psychedelics: What, why, when, and how often? Insights from an international survey of people who use psychedelics” Led by Rotem Petranker and Omer Syed, we provide a global snapshot of microdosing practices across 90 countries and 19 languages
🍄First publication from the Global Psychedelic Survey 2025! Perspectives on microdosing now published in the International Journal of Drug Policy. sciencedirect.com/science/ar… @JacobSAday
1
223
Jacob S. Aday, Ph.D. retweeted
Microdosing psychedelics: What, why, when, and how often? Insights from an international survey of people who use psychedelics
doi.org/10.1016/j.drugpo.202…
2
10
820
Jacob S. Aday, Ph.D. retweeted
George Mashour, Director of the Michigan Psychedelic Center and founder of the Center for Consciousness Science, explores the mind not only through psychedelic neuroscience but also through psychedelic rock music. He just released "Blind Rainbows", his second album.🎸🎹🪘🎤
1
12
664
Jacob S. Aday, Ph.D. retweeted
In 1972 psychologist of religion Walter Clark posted a survey for people doing or interested in doing psychedelic research, and published the first 100 responses. Never knew about this paper until now. “Psychedelic Research: Obstacles and Values”, J Humanistic Psychology, 1975.
2
9
602
Jacob S. Aday, Ph.D. retweeted
PSYCHEDELICS & PAIN: New review by Michigan Psychedelic Center team members Kevin Boehnke, Niloufar Pouyan, and Jacob Aday.
link.springer.com/article/10…
2
6
230
Jacob S. Aday, Ph.D. retweeted
⭐️INCREDIBLE NEWS⭐️ Dr. Kevin Boehnke, Associate Director of the Michigan Psychedelic Center, awarded a >$3M grant from the National Institutes of Health to lead a national study of psychedelics! Learn more about the team and study here: reporter.nih.gov/search/7nI6… CONGRATS, Kevin!
3
12
625
Jacob S. Aday, Ph.D. retweeted
Classic Psychedelics for Chronic Pain: A Critical Review of the Literature and Practical Advice for Clinicians
link.springer.com/article/10…
3
14
672
Jacob S. Aday, Ph.D. retweeted
I am looking for someone to join @Psyched_Alpha to research and write about psychedelic drug development and roll-out with me.
Do you know someone? Please let me know!
jobs.psychedelicalpha.com/jo…
1
6
32
3,123
Jacob S. Aday, Ph.D. retweeted
Happy to share our (@sdpnayak @rick_strassman & Cliff Quals) new publication titled "5-HT1A receptor blockade potentiates the subjective effects of DMT" which is a bayesian analysis of previously collected data by @rick_strassman journals.sagepub.com/doi/10.…
2
8
13
6,373
Jacob S. Aday, Ph.D. retweeted
The methodology for controlling psychedelic trials is *not* undiscovered but let's put that aside for a minute - very sincerely, to some of the of the smartest vocal critics I can immediately think of - what would "good enough" blinding look like? @RecoveryDoctor @madras_bertha @AmitEtkin, others?
So what this means is that placebo-controlled trials are useless in understanding whether psychedelics (or other drugs that affect consciousness) work for any condition. @FDA needs to listen to this. We need an as yet undiscovered methodology for studying them. @TheBorisLab
4
3
17
3,928
Jacob S. Aday, Ph.D. retweeted
Extended difficulties after psychedelic experiences: Prevalence and associations in a global, multilingual sample
assets-eu.researchsquare.com…
2
19
1,289
Jacob S. Aday, Ph.D. retweeted
2 mg Produces Similar Remission to 20 mg in Helus Pharma’s Small Phase 2 Study of Deuterated DMT in Generalised Anxiety Disorder
$HELP tumbles on the news.
2
2
22
10,630